OS Therapies Advances Toward 2026 Osteosarcoma Drug Launch with FDA RMAT Designation
OS Therapies Inc. achieves critical regulatory milestones for its OST-HER2 immunotherapy, positioning for potential accelerated approval and U.S. commercial launch in 2026 to address a 40-year treatment gap in osteosarcoma.
Stonegate Capital Partners has initiated coverage on OS Therapies Inc. (NYSE: OSTX), highlighting the company's significant progress toward bringing its lead immunotherapy candidate OST-HER2 to market for recurrent pulmonary metastatic osteosarcoma. The FDA confirmed that OST-HER2 meets the biological definition of a Regenerative Medicine Advanced Therapy (RMAT) and issued a Biologics License Application number in preparation for accelerated approval submission, marking a crucial regulatory advancement.
Final 12-month Event Free Survival results from the Phase 2b trial demonstrated statistically significant improvement, supported by interim 2-year Overall Survival data, further validating the clinical benefit of the listeria-based immunotherapy platform. This development is particularly significant given that osteosarcoma has seen no new FDA-approved therapies in over 40 years, creating substantial unmet medical need. The company has secured a U.S. commercial partnership with Eversana and is positioning for a potential U.S. launch in the first half of 2026.
Beyond osteosarcoma, OS Therapies expanded its portfolio by acquiring Ayala's listeria immunotherapy platform, adding four clinical-stage and eight pre-clinical programs. The company also formed OS Animal Health to explore applications of OST-HER2 in canine osteosarcoma, supported by positive veterinary trial data. Regulatory progress continues internationally with an ILAP submission to the UK MHRA and an EMA rapporteur meeting scheduled for October 2025, with agencies signaling intent to synchronize reviews via Project Orbis.
Financially, OS Therapies reported a net loss of $4.5M for 2Q25 compared to $1.6M in 2Q24, reflecting increased R&D and G&A expenses related to clinical and regulatory progress. Cash stood at $2.8M at quarter-end, with recent financing extending runway into 2027 through warrant exchanges totaling $7.9M. The company terminated its equity line of credit citing reduced burn rate and sufficient liquidity. If approved before September 30, 2026, OST-HER2's rare pediatric disease designation could qualify the company for a Priority Review Voucher potentially monetizable at approximately $155-160M based on recent transactions.
Stonegate Capital Partners' valuation model returns a range of $7.09 to $9.94 with a midpoint of $8.29 based on a probability-adjusted Discounted Cash Flow analysis using discount rates between 12.50% and 17.50%. The valuation is highly leveraged to long-term outcomes due to the nature of the biotechnology industry, creating potential for significant re-ratings as new clinical and regulatory information emerges. The company's strengthened balance sheet combined with potential PRV monetization provides multi-year capital runway to support commercialization efforts.